Pharmacokinetics of Antiretroviral Agents in Pregnant Individuals Living With HIV: Current Status and Considerations for Study Design and Interpretation

Determining the appropriate dosing regimens of antiretroviral (ARV) drugs for pregnant individuals living with HIV‐1 infection is critical to maximize maternal health and prevent perinatal HIV transmission. Throughout pregnancy, pharmacokinetics (PK) of ARVs can be significantly altered due to physi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2023-06, Vol.63 (S1), p.S176-S187
Main Authors: Choi, Su‐Young, Yang, Xiaoxia, Belew, Yodit, Struble, Kimberly, Reynolds, Kellie
Format: Article
Language:English
Subjects:
Anti-Retroviral Agents - therapeutic use
Antiretroviral agents
Antiretroviral drugs
antiretrovirals (ARVs)
Cobicistat
Disease transmission
Dosage
Drug development
Female
HIV
Human immunodeficiency virus
Humans
Pharmacokinetics
postpartum
Postpartum Period
Pregnancy
Research Design
Ritonavir
Ritonavir - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Determining the appropriate dosing regimens of antiretroviral (ARV) drugs for pregnant individuals living with HIV‐1 infection is critical to maximize maternal health and prevent perinatal HIV transmission. Throughout pregnancy, pharmacokinetics (PK) of ARVs can be significantly altered due to physiological, anatomic, and metabolic changes. As such, conducting PK studies of ARVs during pregnancy is crucial to optimize dosing regimens. In this article, we summarize available data, key issues, challenges, and considerations in interpreting results of ARV PK studies in pregnant individuals. Discussion topics include the choice of the reference population (postpartum vs historical control), pregnancy trimester‐dependent changes in ARV PK, effects of pregnancy on once‐ versus twice‐daily dosing, factors to consider for ARVs that are administered with a PK booster such as ritonavir and cobicistat, and considerations when evaluating the effects of pregnancy on unbound ARV concentrations. Common approaches for the translation of the results into clinical recommendations and rationales and considerations when making clinical recommendations are summarized. Currently, limited PK data in pregnancy are available with long‐acting ARVs. Collection of PK data to characterize the PK profile of long‐acting ARVs is an important goal shared by many stakeholders.
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.2231